UCSF and Eli Lilly launched the new initiative, called AutoImmunoprofiler, which inherits the most successful aspects of its predecessor and adapts them to the study of autoimmune disease (Link).
February 17, 2021
August 5, 2020
NCI OCG Guest Editorial on the Immunoprofiler Consortium. (Link)
January 1, 2019
With our 5th and final consortia partner joining Immunoprofiler, our Cancer program in its current iteration is now closed. Immunoprofiler also adds a new assay (CyTOF) to its repertoire as part of its broad profiling trajectory
January 1, 2018
Immunoprofiler adds new assays (scRNAseq and whole exome sequencing) to its repertoire as part of its broad profiling trajectory.
October 11, 2016
Abbvie joins the UCSF Immunoprofiler consortium.
August 16, 2016
Investigators at the UCSF Immunoprofiler discover prognostic indicators within human melanoma cancers (Link).
August 8, 2016
Investigators at the UCSF Immunoprofiler discover new mechanisms that the immune system uses to recognize tumors (Link).
October 1, 2015
UCSF Immunoprofiler begins profiling human ovarian cancers.
December 31, 2015
Amgen joins the UCSF Immunoprofiler consortium.
January 1, 2015
Bristol-Myers Squibb joins the UCSF Immunoprofiler consortium.
August 1, 2014
The UCSF Immunoprofiler attracts a $100,000 grant from the Helen Diller Cancer Comprehensive Center at UCSF to extend our initiative.
October 16, 2014
Investigators at the UCSF Immunoprofiler identify a rare immune cell population that predicts overall survival across multiple human cancers (Link).
Pre-2013
The UCSF Immunoprofiler launches. UCSF begins profiling human melanoma cancers.
